期刊文献+

匹伐他汀钙对老年冠心病患者肝功能影响的观察 被引量:1

原文传递
导出
摘要 目的:观察匹伐他汀钙片治疗老年冠心病对患者肝功能的影响。方法:选择口服辛伐他汀出现肝功能异常的老年冠心病30例,分别于停用辛伐他汀片、改服匹伐他汀钙片治疗后第2、第4、第8周检测肝功能、血脂水平。结果:改用匹伐他汀钙片治疗后第2、第4、第8周,患者谷丙转氨酶(ALT)、谷草转氨酶(AST)水平均显著或非常显著低于开始治疗时(P<0.05,P<0.01);总胆固醇、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇水平治疗前后差异不显著(P>0.05)。结论:匹伐他汀钙治疗老年冠心病降血脂效果与辛伐他汀相当,且对肝功能损害较轻。
出处 《人民军医》 2011年第8期707-708,共2页 People's Military Surgeon
  • 相关文献

参考文献9

  • 1Mukhtar RY,Reid J, Reckless JP. Pitavastatin [J]. Int J Clin Pract, 2005,59(2) : 239-252.
  • 2Bolego C,Poli A, Cignarella A , et al. Novel statins : Pharmacological and clinical results [J]. Cardiovasc Drugs Ther,2002,16(3) :251-257.
  • 3Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynmrac alterations of 3-hydroxy-3-methylgiutaryl coenzyrne A(HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolicenzyme functions [J]. Pharmacol Ther, 2006,112(1) :71- 105.
  • 4Fujino H,Yamada I,Shirnada S,et al, Metabolic fate of pitavastatin (NK-104) ,a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans [J]. Arzneim Ittelforschtm4g, 2002,52 (10): 745-753.
  • 5Kajinami K, Mabuchi H, Saito Y, et al. NK-104 : A novel synthetic HMG-CoA reductase inhibitor[J]. Expert Opin Invest Drugs, 2000,9 (11) :2653-2661.
  • 6Reinoso RF,Sdnchez-Navano A,Carcia MJ ,et al. Preclinical pharmacokinetics of statins[J]. Methods Find Exp Clin Phamacol, 2002, 24 (9) :593-613.
  • 7何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 8许筱,申屠建中,胡应江.匹伐他汀的药理作用及临床应用[J].中国新药杂志,2009,18(5):383-386. 被引量:20
  • 9Wierzbicki AS,Poston R,Ferro A. The lipid and non-lipid effects of statins[J]. Pharmacol Ther,2003,99(1) :95-112.

二级参考文献53

  • 1何玉红,须媚.降血脂药 匹伐他汀(pitavastatin)[J].世界临床药物,2005,26(3):187-187. 被引量:3
  • 2何笑荣,邹定,姜文清,马捷,李金娥.降血脂新药匹伐他汀[J].中国新药杂志,2005,14(4):483-487. 被引量:32
  • 3张月兰,田文,张子新,曾定尹,齐国先.匹伐他汀对Klotho基因敲除杂合子小鼠血管新生的促进作用[J].中国应用生理学杂志,2006,22(2):163-167. 被引量:3
  • 4张月兰,程颖,李轶男,曾定尹,齐国先.不同剂量匹伐他汀对小鼠缺血肢血流恢复的影响[J].中国医科大学学报,2006,35(3):251-252. 被引量:2
  • 5BOLEGO C, POLI A, CIGNARELLA A, et al. Novel statins: Pharmacological and clinical results [ J ]. Cardiovasc Drugs Ther, 2002,16(3) : 251 -257.
  • 6SUZUKI M, IWASAKI H, FUJIKAWA Y, et al. Synthesis and biological evalutions of quinoline-based HMG-CoA reductase inhibitors[ J]. Bioarg Med Chem,2001,9 (10) : 2727 -2743.
  • 7SATA M, NISHIMATSU H, SLZUKI E, et al. Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia [J]. FASEB J, 2001, 15(13):2530-2532.
  • 8POURATI I, KIMMELSTIEL C, RAND W, et al. Statin use is associated with enhanced collateralization of severely diseased coronary arteries[ J ]. Am Heart J, 2004, 148 (5) : 21 - 23.
  • 9TOKORO T, WANG J, KITAJIMA I, et al. The novel HMG- CoA reductase inhibitor, pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO)[J]. Yakugaku Zasshi, 2004,124(3) :121 -126.
  • 10WANG JY, TOKORO T, HIGA S,et al. Anti-inflammatory effect of ptavastatin on NF-KB activated by TNF-a in hepatocellular carcinoma Ceils [ J ]. Biol Pharm Bull ,2006,29 ( 4 ) :634 - 639.

共引文献46

同被引文献13

  • 1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5233
  • 2武阳丰,赵冬,周北凡,王薇,李贤,刘静,李莹,孙佳艺,赵连成,吴兆苏,诸骏仁.中国成人血脂异常诊断和危险分层方案的研究[J].中华心血管病杂志,2007,35(5):428-433. 被引量:176
  • 3刘梅林.老年人他汀治疗:获益与安全性的平衡[N].中国医学论坛报,2009-05-07(C8).
  • 4赵水平.临床血脂领域年度事件评说[N].中国医学论坛报,2011-01-06.C3版.
  • 5赵水平.血脂异常l临床防治[M].北京:中华医学电子音像出版社,2010:67-75,154-157.
  • 6姚康.动脉粥样硬化防治:永恒的话题,崭新的视角[N].中国医学论坛报,2013-10-10(A16).
  • 7Fabijanie D, Banie M,Kardum D. C -reactive protein in cardiovas- cular risk evaluation [ J ]. Lijec Vjesn,2006,128 ( 5/6 ) : 176 - 174.
  • 8Ridker PM, Danielson E, Francisco A, et al. Rosuvastatin to prevent vascular events in men and women with elevated C - reactive protein [J]. N Engl J Med,2008 ,359( 21 ) :2195 -2207.
  • 9Kosbiyama H,Taniguchi A,Tanaka K, et al. Effects of Pitavastatin on Lipid Profiles and High-sensitinty CRP in Janpanese Subjects with Hypercholesterolemia. Kansai Investigation of statin for Hyperlipidem- ic Intrevention in Metabolism and Endocrinology (KISHIMEN)Inves- tigators[ J]. J Atheroscler Thromb ,2008,15 (6) :345 - 350.
  • 10Matsubara T, Nakao M, Marui N, et al. Impact of pitarastatin on high-sensitinty C -reactive protein and adiponeetion and adiponee- tin hypercholesterolemic patients with the metabolic syndrome:The PREMIUM Study [ J ]. J Cardiol,2012,60 ( 5 ) : 389 - 394.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部